Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab by Topp, M.S. et al.
554 Cancer  February 15, 2021
Original Article
Long-Term Survival of Patients With Relapsed/Refractory Acute 
Lymphoblastic Leukemia Treated With Blinatumomab
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BACKGROUND: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells ex-
pressing CD19. METHODS: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily 
pretreated adults with Philadelphia chromosome–negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was con-
ducted. RESULTS: A total of 259 patients were included in the analysis. The median overall survival (OS) among all patients, regardless of 
response, was 7.5 months (95% confidence interval [CI], 5.5-8.5 months); the median follow-up time for OS was 36.0 months (range, 0.3-
60.8 months). The median relapse-free survival (RFS) among patients who achieved a complete remission (CR) or complete remission 
with partial hematologic recovery (CRh) in the first 2 cycles (n = 123) was 7.7 months (95% CI, 6.2-10.0 months); the median follow-up 
time for RFS was 35.0 months (range, 9.5-59.5 months). OS and RFS plateaued with 3-year rates of 17.7% and 23.4%, respectively. The cu-
mulative incidence function of the time to relapse, with death not due to relapse considered a competing risk, for patients who achieved 
a CR/CRh within 2 cycles of treatment also plateaued with a 3-year relapse rate of 59.3%. For patients who achieved a CR/CRh with 
blinatumomab followed by allogeneic hematopoietic stem cell transplantation while in continuous CR, the median OS was 18.1 months 
(95% CI, 10.3-30.0 months) with a 3-year survival rate of 37.2%. CONCLUSIONS: These data suggest that long-term survival is possible 
after blinatumomab therapy. Cancer 2021;127:554-559. © 2020 Amgen GmbH. Cancer published by Wiley Periodicals LLC on behalf of 
American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and 
no modifications or adaptations are made. 
LAY SUMMARY: 
• Immuno-oncology therapies such as blinatumomab activate the patient’s own immune system to kill cancer cells.
• This study combined follow-up data from 2 blinatumomab-related clinical trials to evaluate long-term survival in patients with relapsed 
and/or refractory B-cell precursor acute lymphoblastic leukemia at high risk for unfavorable outcomes.
• Among patients who achieved a deep response with blinatumomab, one-third lived 3 years or longer. These findings suggest that long-
term survival is possible after treatment with blinatumomab. 
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INTRODUCTION
Patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) have a poor prognosis, with 
allogeneic hematopoietic stem cell transplantation (HSCT) generally viewed as the only curative option.1-3 However, 
immuno-oncology therapy with blinatumomab, BiTE (a bispecific T-cell engager) molecule, has led to long-term sur-
vival among responders even in the absence of HSCT.4 In a phase 3 study of heavily pretreated adults with R/R ALL, the 
median overall survival (OS) was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group 
(P = .01). The median duration of follow-up was 11.7 and 11.8 months, respectively. The study was stopped early 
 because the threshold for an OS benefit was met at the interim analysis.5
We pooled long-term follow-up data from 2 single-arm, phase 2 studies (NCT01209286 and NCT01466179) 
to assess the durability of response to blinatumomab in patients with R/R ALL.6,7 In the primary analyses of the 2 
phase 2 studies, the median durations of follow-up for OS and relapse-free survival (RFS) were relatively short: 12.1 
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and 9.7 months, respectively, in the exploratory phase 2 
study (n = 36)7 and 9.8 and 8.9 months, respectively, in 
the confirmatory phase 2 study (n = 189).6 An additional 
analysis of the 36 adults in the exploratory study after a 
median follow-up of 32.6 months found that a plateau 
was reached for both RFS and OS.8 Here, we report the 
long-term RFS and OS from the pooled phase 2 studies 
to further substantiate long-term survival outcomes after 
therapy with blinatumomab.
MATERIALS AND METHODS
The design and conduct of the 2 studies included in 
this analysis have been published.6,7 In brief, both were 
open-label, single-arm, phase 2 studies in adult patients 
with R/R B-cell precursor ALL. The study protocols 
were approved by the independent ethics committee 
of each study site, and all patients provided written in-
formed consent before any study-specific procedures were 
performed. Overall, 259 patients with Philadelphia 
chromosome–negative disease were included in this anal-
ysis; 2 patients with Philadelphia chromosome–positive 
disease from the confirmatory study were excluded.
In both studies, a treatment cycle consisted of a 
continuous intravenous infusion of blinatumomab for 
4 weeks followed by a 2-week treatment-free interval.6,7 
Patients in the dose-finding part of the exploratory study 
received blinatumomab at 15 µg/m2/d over the entire 
treatment period; at 5 µg/m2/d in week 1 and then at 
15 µg/m2/d thereafter; or at 5 µg/m2/d in week 1, at 
15 µg/m2/d in week 2, and at 30 µg/m2/d thereafter.7 
Patients in the confirmatory study received blinatum-
omab at 9 μg/d in week 1 and at 28 μg/d thereafter.6
Kaplan-Meier estimates of median OS and median 
RFS and rates of OS and RFS were determined for the 
overall patient population; the Kaplan-Meier estimate of 
median OS was also determined for patients who under-
went HSCT. Because a failure to consider competing risks 
can lead to biased results when the follow-up period is 
long, the cumulative incidence function of the time to 
relapse, with death not due to relapse considered a com-
peting risk, was determined for patients who achieved a 
complete remission (CR) or complete remission with par-
tial hematologic recovery (CRh) within 2 cycles.
Patient clinical outcomes are presented by survival sta-
tus: <36-month OS or ≥36-month OS (alive at the month 
36 follow-up). Most events occur within 24 months of treat-
ment initiation.1 The evaluated clinical outcomes were the 
best overall response in the first 2 cycles, the minimal residual 
disease (MRD) response after blinatumomab (<10−4 detect-
able blasts by quantitative polymerase chain reaction), the 
proportion of patients who underwent HSCT, and the pro-
portions of relapse-free survivors with and without HSCT. 
Cox regression modeling was used to explore the relation-
ship between baseline and postbaseline factors and OS and 
RFS; postbaseline factors were modeled as time-dependent 
covariates.
RESULTS
In this pooled analysis of 259 patients, the baseline char-
acteristics were similar to those of patients in individual 
trials (Table 1).6,7 The baseline characteristics, the number 
of treatment cycles, and the outcomes by RFS and OS sta-
tus with and without HSCT are provided in the support-
ing information (Supporting Tables 1 and 2). The median 
OS was 7.5 months (95% confidence interval [CI], 5.5-
8.5 months) after a median follow-up duration of 36.0 
months (range, 0.3-60.8 months; Fig. 1A). The median 
RFS for those who achieved a CR/CRh in the first 2 cycles 
(n = 123) was 7.7 months (95% CI, 6.2-10.0 months) 











Black (or African American) 7 (2.7)
American Indian or Alaska Native 1 (0.4)
Native Hawaiian or other Pacific Islander 1 (0.4)
Other 12 (4.6)
Unknown 25 (9.7)
Primary refractory, No. (%) 25 (9.7)
Prior relapses, No. (%)
1 146 (56.2)
≥2 88 (34.0)





Mean (SD), % 66.7 (31.1)
Bone marrow blasts, No. (%)
≤5% 6 (2.3)
>5 to <10% 10 (3.9)
10 to <50% 61 (23.6)
≥50% 178 (68.7)
Unknown 4 (1.5)
Cytogenetic factors, No. (%)
t(4;11) 16 (6.2)





Abbreviations: ECOG, Eastern Cooperative Oncology Group; HSCT, hemat-
opoietic stem cell transplantation; SD, standard deviation.
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Figure 1. OS, RFS, and cumulative incidence function of the time to relapse: (A) OS KM curve and estimates at specific time points 
for the overall patient population, (B) RFS KM curve and estimates at specific time points for the overall patient population, (C) OS 
KM curve for patients who underwent HSCT after achieving a CR/CRh, and (D) cumulative incidence function of the time to relapse 
and estimates at specific time points for the overall patient population. OS was measured from the time of the first blinatumomab 
dose to death from any cause, and RFS was measured from the time of first CR or CRh within the first 2 cycles to hematologic 
or extramedullary relapse or death resulting from any cause. Patients who were alive were censored on the last documented visit 
date or the date of the last phone contact. The cumulative incidence function of the time to relapse with death from nonrelapse 
as a competing risk was determined for patients who achieved a CR/CRh within 2 cycles of treatment. Error bars represent 95% 
confidence intervals. CR indicates complete remission; CRh, complete remission with partial hematologic recovery; HSCT, allogeneic 





Long-Term Survival With Blinatumomab/Topp et al
557Cancer  February 15, 2021
after a median follow-up duration of 35.0 months (range, 
9.5-59.5 months; Fig. 1B). OS and RFS rates plateaued 
after 3 years of follow-up with 2-, 3-, 4-, and 5-year rates 
of 23.4%, 17.7%, 15.8%, and 15.8%, respectively, for OS 
and with 2-, 3-, and 4-year rates of 26.9%, 23.4%, and 
23.4%, respectively, for RFS (Fig. 1A,B). The median OS 
of patients who achieved a CR/CRh with blinatumomab 
followed by HSCT while in continuous CR was 18.1 
months (95% CI, 10.3-30.0 months; Fig. 1C).
The cumulative incidence function of the time to 
relapse, with death not due to relapse considered a com-
peting risk, for patients who achieved a CR/CRh within 
2 cycles of treatment also plateaued with 2-, 3-, 4-, and 
5-year relapse rates of 56.7%, 59.3%, 59.3%, and 63.2%, 
respectively (Fig. 1D).
Long-term survivors (those surviving for ≥36 
months) were more likely to have achieved a CR/CRh, to 
have an MRD response, and to have undergone HSCT 
than those surviving for <36 months (Table 2). In univar-
iate analyses, the Eastern Cooperative Oncology Group 
performance status at the baseline, achieving a CR/CRh 
during the study, and achieving an MRD response during 
the study were associated with OS. In the multivariate anal-
ysis, achieving a CR/CRh during the study and achieving 
an MRD response during the study were associated with 
OS (Table 3). Twenty-seven of the 43 long-term survivors 
(62.8%) were relapse free at 36 months. Nineteen of the 
27 relapse-free survivors (70.4%) underwent HSCT after 
blinatumomab while in continuous CR, and 8 (29.6%) 
survived relapse free after blinatumomab without HSCT. 
In univariate analyses, race, t(4;11) status at the baseline, 
and achieving an MRD response during the study were 
associated with RFS. In the multivariate analysis, race and 
t(4;11) status at the baseline were associated with RFS 
(Table 3).
DISCUSSION
Immuno-oncology therapy is a major advancement in the 
treatment of patients with previously incurable disease. 
This is especially true for patients with R/R ALL enrolled 
in blinatumomab phase 2 trials because they are at high 
risk for an unfavorable outcome, a short time to first re-
lapse, prior HSCT, and later lines of salvage therapy.6,7 In 
this pooled analysis, OS and RFS plateaued after 3 years 
of follow-up with encouraging long-term survival rates 
in light of the historically poor rates with conventional 
chemotherapy.1,9 The cumulative incidence function of 
the time to relapse, with death not due to relapse con-
sidered a competing risk, also plateaued. Because mortal-
ity unrelated to relapse may be substantial during a long 
follow-up period, this analysis suggests that more than 
one-third of patients who achieve a CR/CRh with blina-
tumomab therapy meet the criteria for a cure.10 When the 
relationships between various factors and survival were 
explored, achieving a CR/CRh and achieving an MRD 
response were strong predictors of OS. The survival 
TABLE 2. Clinical Outcomes After Blinatumomab Treatment
Clinical Outcome
Patients Who Survived ≥36 mo  
(n = 43)a




Best response within 2 cycles, No. (%)
CR 27 (62.8) 60 (27.8) 87 (33.6)
CRh 9 (20.9) 27 (12.5) 36 (13.9)
Hypocellular bone marrow 1 (2.3) 2 (0.9) 3 (1.2)
MRD responders, No. (%)b 35 (81.4) 72 (33.3) 107 (41.3)
MRD response during cycle 1c 32 (91.4) 65 (90.3) 97 (90.7)
MRD response during cycle 2c 2 (5.7) 5 (6.9) 7 (6.5)
MRD response during cycle 3 and beyondc 1 (2.9) 2 (2.8) 3 (2.8)
HSCT after blinatumomab, No. (%) 24 (55.8) 56 (25.9) 80 (30.9)
In remission after achieving CR/CRh within 2 cycles 21 (48.8) 35 (16.2) 56 (21.6)
Achieved CR/CRh within 2 cycles but relapsed 
before HSCT
1 (2.3) 7 (3.2) 8 (3.1)
HSCT without CR/CRh within 2 cycles 2 (4.7) 14 (6.5) 16 (6.2)
Relapse-free survivor after blinatumomab, No. (%) 27 (62.8) 2 (0.9)d 29 (11.2)
Blinatumomab only 8 (18.6) 1 (0.5) 9 (3.5)
HSCT after blinatumomab in CCR 19 (44.2) 1 (0.5) 20 (7.7)
Abbreviations: CCR, continuous complete remission; CR, complete remission; CRh, complete remission with partial hematologic recovery; HSCT, allogeneic he-
matopoietic stem cell transplantation; MRD, minimal residual disease.
aPatients known to be alive after 35 months were considered long-term survivors in the analysis to account for a ±4-week window for the month 36 survival 
follow-up.
bAt any time during treatment with blinatumomab.
cPercentages are based on the number of MRD responders.
dTwo patients in the <36-month group in whom disease had not relapsed were lost to follow-up before their final visit and could not be considered long-term 
survivors.
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advantage of achieving MRD negativity in both adults 
and children has been demonstrated in other studies, in-
cluding a meta-analysis of 39 studies.11
Long-term results have also begun to emerge with 
other targeted therapies.12,13 The reported OS rates for 
the anti-CD22 antibody-drug conjugate inotuzumab 
ozogamicin and CD19-directed chimeric antigen recep-
tor T-cell therapy are difficult to compare with the cur-
rent analysis because of the different patient populations 
in the blinatumomab, inotuzumab ozogamicin, and chi-
meric antigen receptor T-cell therapy studies. However, 
all these treatment regimens represent meaningful clinical 
advancements over standard chemotherapy.
Survival after blinatumomab compares favorably 
with published data evaluating chemotherapy after re-
lapse.9,14 Among relapsed patients with ALL treated 
with salvage chemotherapy, no patients without HSCT 
survived for more than 1 year after relapse.1 Of the 43 
long-term survivors reported here, 19 (44.2%) survived 
without HSCT, and 8 (18.6%) remained relapse free 
without HSCT for 3 or more years.
Although our results are strengthened by the large 
sample size and the long duration of follow-up, they are 
limited by the retrospective nature of the analysis and the 
inclusion of data pooled from 2 trials.
In summary, these long-term follow-up data suggest 
that a cure after blinatumomab therapy is most common 
in patients undergoing HSCT in CR, although a cure is 
possible in some patients after blinatumomab only, espe-
cially when MRD is eliminated.
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